Clinical trials: Heart Failure; With Decompensation
Heart Failure
Reducing Decompensation Events Utilizing Intracardiac Pressures in Patients With Chronic Heart Failure (HF) (REDUCEhf)
The purpose of this clinical research study is to evaluate the safety and effectiveness of the investigational implantable hemodynamic monitor (IHM), and of the IHM in combination with an implantable cardioverter defibrillator…
- Trial name
- REDUCEhf (NCT00354159)
- Testing
- Implantable Hemodynamic Monitor (Chronicle® IHM), and IHM in combination with single chamber ICD (Chronicle ICD)
- Where
- 52 sites in United States
- Volunteers
- 442 people
- Sponsor
- Medtronic Cardiac Rhythm and Heart Failure
Acute Heart Failure
Intravenous Vasodilator vs. Inotropic Therapy in Patients With Heart Failure
Single center, prospective, randomized, non-blinded research study comparing intravenous vasodilator infusion vs. inotropic infusion in patients admitted to the hospital or in the emergency room at Montefiore Medical Center…
- Trial name
- PRIORITY-ADHF (NCT02767024)
- Testing
- Sodium nitroprusside, Dobutamine, Furosemide
- Where
- United States
- Sponsor
- Montefiore Medical Center
Heart Decompensation
Levosimendan Compassionate Use in Pediatric Patients With Advanced Decompensated Heart Failure
Open label study of levosimendan; planned comparison for effectiveness and safety to historic matched case controls from participating sites.
- Trial name
- NCT02973620
- Testing
- Levosimendan
- Sponsor
- Tenax Therapeutics, Inc.
Heart Failure; With Decompensation
Targeting LOXL2 and Cardiac Fibrosis for Post-acute Heart Failure Treatment- A Prospective Study
A previous study demonstrated that a multidisciplinary cardiac rehabilitation (CR) program was associated with reduced medium- to long-term all-cause mortality in a retrospective propensity score-matched study.
- Trial name
- NCT05498584
- Testing
- exercise based cardiac rehabilitation
- Where
- Taiwan
- Volunteers
- 130 people
- Sponsor
- Chang Gung Memorial Hospital
Heart Failure, Ventricular Dysfunction
Effects of Nesiritide in Pediatric Patients With Heart Failure
Children with severe heart failure need immediate appropriate care. New and better drugs are constantly being developed. As these drugs are approved for adult use, they are used off-label for children.
- Conditions
- Heart Failure, Ventricular Dysfunction, Heart Decompensation
- Trial name
- NCT00166010
- Testing
- Nesiritide
- Sponsor
- Emory University
Heart Decompensation
Short-term Efficacy of Furosemide, Isosorbide Dinitrate and Their Combination in ADHF
Background: Acute decompensated heart failure (ADHF) is a common and potentially fatal cause of acute respiratory distress that requires immediate treatment in emergency department.
- Trial name
- NCT02649998
- Testing
- Furosemide, Isosorbide Dinitrate
- Where
- Hong Kong
- Sponsor
- Chinese University of Hong Kong
Heart Failure, Cognitive Impairment
Cognitive Impairment in Patients With Heart Failure
The aim of the present study is threefold: investigating 1) specific cognitive impairments in patients with congestive heart failure, 2) whether cognitive impairments in patients with decompensated heart failure improve after…
- Trial name
- CogImpairHF (NCT00837889)
- Testing
- diuretics, inotropica
- Where
- 2 sites in Germany
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Universität des Saarlandes
Heart Failure; With Decompensation, Cardiorenal Syndrome
The Aortix CRS Pilot Study
The Aortix CRS Pilot Study: An Evaluation of the Safety and Performance of the Aortix System for Intra-Aortic Mechanical Circulatory Support in Patients with Cardiorenal Syndrome
- Conditions
- Heart Failure; With Decompensation, Cardiorenal Syndrome, Cardio-Renal Syndrome, Heart Failure
- Trial name
- NCT04145635
- Testing
- Aortix System
- Where
- 19 sites in United States, Australia
- Volunteers
- 21 people
- Sponsor
- Procyrion
Heart Failure, Acute Coronary Syndrome
Big Data to Assess the Healthcare and Health Outcomes Burden of Acute Coronary Syndromes Complicated With Heart Failure
The goal of this observational study is to define the incidence of heart failure (HF) after acute coronary syndrome (ACS). The main question it aims to answer is: To define HF incidence in the medium and long-term in the context…
- Conditions
- Heart Failure, Acute Coronary Syndrome, Heart Decompensation, Myocardial Infarction, Acute
- Trial name
- BEAT-HF (NCT06255418)
- Where
- Spain
- Volunteers
- 7,860,560 people
- Sponsor
- Hospital Universitari de Bellvitge
Acute Heart Failure, Cardiac Decompensation
Global rEgistry on decongestioN Therapy Using Less invasivE UltraFiltration
In patients with advanced volume overload, minimally invasive ultrafiltration treatment in the acute phase can have a positive effect on clinical outcome.
- Conditions
- Acute Heart Failure, Cardiac Decompensation, Volume Overload
- Trial name
- GENTLE-UF (NCT02769351)
- Testing
- periph. minimal invasive ultrafiltration
- Where
- 19 sites in Germany, Sweden and 1 more
- Volunteers
- 104 people
- Sponsor
- Fresenius Medical Care Deutschland GmbH
Heart Failure, Patient Empowerment
Remote Patient Monitoring for Patients With Heart Failure in France
The goal of this multicenter observational longitudinal cohort study is to evaluate the ability of a Remote Patient Monitoring (RPM) program to prevent cardiac decompensation by detecting weak signals of decompensation early in…
- Conditions
- Heart Failure, Patient Empowerment, Cardiac Failure
- Trial name
- TELESAT-HF (NCT06312501)
- Testing
- Satelia®Cardio, Conventional care
- Where
- France
- Volunteers
- 20,000 people
- Sponsor
- Satelia
Acute Heart Failure, Acute Decompensation of Chronic Heart Failure
Tezosentan in Acute Heart Failure
The randomized patients with acute heart failure will be stratified based on the presence or absence of a Swan-Ganz catheter and assigned to receive either tezosentan 5 mg/h for the first 30 minutes and 1 mg/h thereafter or…
- Conditions
- Acute Heart Failure, Acute Decompensation of Chronic Heart Failure, New Onset of Heart Failure
- Trial name
- VERITAS 1 (NCT00525707)
- Testing
- tezosentan
- Where
- 35 sites in United States, Austria and 8 more
- Volunteers
- 735 people
- Sponsor
- Idorsia Pharmaceuticals Ltd.
Heart Failure, Systolic, Heart Failure; With Decompensation
Fluid Restriction in Patients With Heart Failure
There is a concept increasingly consolidated by clinical evidence that at each hospitalization due to HF decompensation there is a substantial loss of quality of life, which is associated with an initial period of great clinical…
- Conditions
- Heart Failure, Systolic, Heart Failure; With Decompensation, Pulmonary Congestion
- Trial name
- NCT04611594
- Testing
- Fluid restriction
- Where
- Brazil
- Volunteers
- 75 people
- Sponsor
- Hospital de Clinicas de Porto Alegre
Heart Failure; With Decompensation, Heart Failure，Congestive
Dietary Sodium Intake in Acute Heart Failure
This study is design to assess two levels of dietary sodium intake in the treatment of patients with Acute Decompensated Heart Failure.
- Trial name
- SODIC (NCT03722069)
- Testing
- Low sodium diet, Normal sodium diet
- Where
- Brazil
- Volunteers
- 44 people
- Sponsor
- University of Sao Paulo
Heart Failure With Decompensation
The Predictors and Benefits of Multi-discipline Disease Management Program in Heart Failure Patients
The investigator will investigate the predictors includes cardiac biomarkers, endothelial function and cardiopulmonary exercise test in prediction of cardiovascular outcome in patients with heart failure discharged from hospital.
- Trial name
- NCT03782337
- Testing
- multi-discipline disease management program
- Where
- Taiwan
- Volunteers
- 162 people
- Sponsor
- Chang Gung Memorial Hospital
Acute Heart Failure, Acute Decompensation of Chronic Heart Failure
Tezosentan in the Treatment of Acute Heart Failure
The randomized patients with acute heart failure will be stratified based on the presence or absence of a Swan-Ganz catheter and assigned to receive either tezosentan 5 mg/h for the first 30 minutes and 1 mg/h thereafter or…
- Conditions
- Acute Heart Failure, Acute Decompensation of Chronic Heart Failure, New Onset of Heart Failure
- Trial name
- VERITAS 2 (NCT00524433)
- Testing
- tezosentan
- Where
- 42 sites in United States, Australia and 6 more
- Volunteers
- 713 people
- Sponsor
- Idorsia Pharmaceuticals Ltd.
Heart Failure
Anticipation and Detection of Heart Failure Decompensation With Automatic Treatment of Informations
Heart failure (HF) is a serious chronic disease with frequent readmissions, some of which can be prevented by early action. The management of HF is complex: long, often difficult and costly.
- Trial name
- e-INCA (NCT02411279)
- Testing
- Equiped group with telemedicine systems
- Where
- France
- Volunteers
- 20 people
- Sponsor
- University Hospital, Strasbourg, France
Heart Failure, Acute Heart Failure
Protocol of Diuretics Use in Congestive Therapy in Heart Failure
The main objective of the study is to determine if a diuretic adaptation protocol in the decompensation of chronic heart failure is more effective but also safer than the current non-protocolized practice.
- Conditions
- Heart Failure, Acute Heart Failure, Chronic Heart Failure
- Trial name
- ProDUCT-HF (NCT03892148)
- Testing
- Furosemide, Hydrochlorothiazide
- Where
- 9 sites in France
- Volunteers
- 299 people
- Sponsor
- University Hospital, Clermont-Ferrand
Cirrhotic Cardiomyopathy, Empagliflozin
DICE Study- Diastolic Improvement With Carvedilol & Empagliflozin in Patients With Cirrhosis
1. This proposed double-blind placebo controlled randomized controlled trial incorporates recent advances in management of heart failure and portal hypertension using the SGLT-2 inhibitor i.e. EMPAGLIFLOZIN.
- Conditions
- Cirrhotic Cardiomyopathy, Empagliflozin, Cardiometabolic Risk Factors, Cirrhosis
- Trial name
- DICE (NCT07322237)
- Testing
- Empagliflozin + Carvedilol, Carvedilol
- Where
- India
- Volunteers
- 400 people
- Sponsor
- Post Graduate Institute of Medical Education and Research, Chandigarh
Heart Decompensation, Acute
Study With Healthy Japanese and Non-Asian Participants With BMS-986231
The purpose of this Phase 1 study is to evaluate the safety, tolerability, PK, and pharmacodynamics (PD) of BMS-986231 in healthy Japanese and Non-Asian participants. There is no formal hypothesis to be statistically tested.
- Trial name
- NCT02932969
- Testing
- BMS-986231
- Where
- United States
- Volunteers
- 56 people, healthy volunteers welcome
- Sponsor
- Bristol-Myers Squibb